The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
PEGylated therapeutics in the clinic
Open accessAbstract
The covalent attachment of polyethylene glycol (PEG) to therapeutic agents, termed PEGylation, is a well‐established and clinically proven drug delivery approach to improve the pharmacokinetics and pharmacodynamics of drugs. Specifically, PEGylation can improve the parent drug's solubility, extend its circulation time, and reduce its immunogenicity, with minimal undesirable properties. PEGylation technology has been applied to various therapeutic modalities including small molecules, aptamers, peptides, and proteins, leading to over 30 PEGylated drugs currently used in the clinic and many investigational PEGylated agents under clinical trials. Here, we summarize the diverse types of PEGylation strategies, the key advantages of PEGylated therapeutics over their parent drugs, and the broad applications and impacts of PEGylation in clinical settings. A particular focus has been given to the size, topology, and functionalities of PEG molecules utilized in clinically used PEGylated drugs, as well as those under clinical trials. An additional section has been dedicated to analyzing some representative PEGylated drugs that were discontinued at different stages of clinical studies. Finally, we critically discuss the current challenges faced in the development and clinical translation of PEGylated agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Babitt, J. L., & Lin, H. Y. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111078 · Cited by 1,041 · cited 1×
“…polycythemia vera), and 11 products are developed to treat disorders with decreased numbers of cells in the blood, including anemia (low levels of red blood cells), 39 paroxysmal nocturnal hemoglobinuria (hemolytic anemia and other manifestations), 40,41 and neutropenia (low levels of neutrophils).”
BackgroundThe clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535
Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514 · cited 2×
“29 In the case of LNPs such as Comirnaty ™ and Spikevax ® , PEGylation is used to enhance stability, decrease aggregation and protect the LNPs from uptake by the MPS. 32 To summarize, PEGylation has been shown to increase the molecular mass and hydrodynamic sizes of small molecules and peptides, play a role in recepto…”
MethodGanson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1861 · Cited by 350
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Padín-González, E., Lancaster, P., Bottini, M., Gasco, P., Tran, L., Fadeel, B., Wilkins, T., & Monopoli, M. P. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.882363 · Cited by 166
Anaphylaxis and Hypotension after Administration of Peginesatide
Bennett, C. L., Jacob, S., Hymes, J., Usvyat, L. A., & Maddux, F. W. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1400883 · Cited by 59
Cited by
The molecular basis for hydrodynamic properties of PEGylated human serum albumin
(2024) · doi:10.1016/j.bpj.2024.05.019 · Cited by 9
Metadata
- Authors
- Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S.
- Venue
- Bioengineering & Translational Medicine
- Publisher
- Wiley
- Published
- 2023-09-22
- Volume
- 9
- Issue
- 1
- Pages
- e10600-e10600
- ISSN
- 2380-6761 (ISSN-L)
- OpenAlex
- W4386981923
- Cited by
- 233
- References
- 14
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.